Bristol-Myers, Pfizer sales and marketing update

The U.K.’s NICE issued final guidance recommending the use of Eliquis apixaban from Bristol-Myers and partner Pfizer to treat and prevent venous thromboembolism (VTE) in adults. The committee said in most of the analyses, the incremental cost-effectiveness ratio (ICER) for the direct Factor Xa inhibitor was less than L20,000 ($30,508) per quality-adjusted life year (QALY) for both the six-month and life-long treatment durations. ...